News - Roche, Chugai Pharmaceutical

Filter

Popular Filters

Japan NHI price listing for Chugai’s Kadcyla delayed

14-11-2013

Japanese drugmaker Chugai Pharmaceutical, which is majority owned by Swiss major Roche, says that the…

Asia-PacificChugai PharmaceuticalKadcylaOncologyPharmaceuticalPricingResearchRoche

Chugai unit seals deal for Helsinn’s anamorelin in top EU markets

12-11-2013

Privately-held Swiss pharmaceutical group Helsinn has granted Chugai Pharma Marketing, a wholly-owned…

anamorelinChugai PharmaceuticalEuropeHelsinnLicensingOncologyPharmaceuticalRoche

Roche and Chugai’s SC RoActemra improves RA long term

Roche and Chugai’s SC RoActemra improves RA long term

28-10-2013

Roche and its majority-owned Japanese subsidiary Chugai Pharmaceutical have announced that their RoActemra…

Anti-Arthritics/RheumaticsAsia-PacificChugai PharmaceuticalPharmaceuticalResearchRoActemraRoche

Chugai gains Japanese approval for Perjeta and Bonviva

28-06-2013

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) said this morning (June 28) that it has obtained…

Anti-Arthritics/RheumaticsAsia-PacificBonvivaChugai PharmaceuticalOncologyPerjetaPharmaceuticalRegulationRoche

Roche affiliate Chugai files for T-DM1 approval in Japan; gains rights to Afraxis compound

30-01-2013

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519), which is majority owned by Swiss major Roche (ROG:…

AfraxisAsia-PacificChugai PharmaceuticalGenentechGlobalLicensingOncologyPharmaceuticalProductionRegulationRocheT-DM1trastuzumab emtansine

Chugai in co-development accord for obinutuzumab with Nippon Shinyaku

28-11-2012

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519), which is majority-owned by Swiss drug major Roche…

BiotechnologyChugai PharmaceuticalLicensingNippon ShinyakuobinutuzumabOncologyPharmaceuticalResearchrituximabRoche

Chugai licenses SGLT2 inhibitor CSG452 in Japan to Kowa and Sanofi

29-10-2012

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519), which is majority owned by Swiss major Roche (ROG:…

Asia-PacificChugai PharmaceuticalCSG452DiabetesKowa PharmaceuticalsLicensingPharmaceuticalRocheSanofi

Chugai first to establish stable cell lines of cancer stem cells

22-10-2012

Chugai Pharmaceutical (TYO: 44519), which is majority-owned by Swiss drug major Roche (ROG: SIX), has…

Chugai PharmaceuticalOncologyPharmaceuticalResearchRoche

Chugai files of Japanese approval of Avastin for ovarian cancer

11-10-2012

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519), which is majority-owned by Swiss drug major Roche…

Asia-PacificAvastinChugai PharmaceuticalOncologyPharmaceuticalRegulationRoche

Chugai pushed into filing for Avastin glioblastoma indication in Japan

21-09-2012

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519), which is majority-owned by Swiss drug major Roche…

Asia-PacificAvastinChugai PharmaceuticalOncologyPharmaceuticalRegulationRoche

Chugai expands in Singapore, opening second satellite research institute

17-07-2012

Chugai Pharmabody Research (CPR), a unit of Swiss pharma major Roche (ROG: SIX) majority-owned Japanese…

Asia-PacificChugai PharmaceuticalFinancialPharmaceuticalResearchRoche

Surveyed US psychiatrists would prescribe Roche/Chugai's bitopertin to 28% of their patients with negative symptoms of schizophrenia

30-05-2012

US psychiatrists surveyed by advisory firm Decision Resources indicate that they would prescribe Roche/Chugai's…

bitopertinChugai PharmaceuticalGlobalMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalRoche

Chugai gets rights to develop Roche’s MetMab and lebrikizumab in Japan

05-09-2011

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519)l has entered into license agreements with its majority…

Asia-PacificChugai PharmaceuticallebrikizumabLicensingMetMAbOncologyPharmaceuticalRespiratory and PulmonaryRoche

Chugai gets rights to Roche melanoma drug vemurafenib in Japan

15-08-2011

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) said yesterday that it has entered into a license…

Chugai PharmaceuticalLicensingOncologyPharmaceuticalRochevemurafenib

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top